SITC features bispecific solutions for solid tumors

In a year when bispecific antibodies have been proving their worth in and beyond cancer, the immuno-oncology–focused SITC meeting advanced the field with innovations that could make the modality more effective against solid tumors.

The modality dominated the abstracts presented at the Society for Immunotherapy of Cancer annual meeting, accounting for more than 100 of the meeting’s 1,300-plus abstracts...